問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林季宏

Recruiting

List

88Cases

2021-07-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2032-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    注射用凍晶粉末 注射劑

Participate Sites
5Sites

Recruiting5Sites

2024-07-01 - 2030-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-07-01 - 2035-12-31

Phase III

Not yet recruiting
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    注射劑 錠劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2017-03-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2023-09-30

Phase I

Completed
A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies

  • Condition/Disease

    Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC),hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, melanoma,renal cell cancer, pancreatic cancer, cervical cancer, and triple negative breastcancer (BC)

  • Test Drug

    KY1044

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Terminated1Sites

2024-04-01 - 2030-01-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-04-01 - 2030-01-31

Phase I/II

Active
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

  • Condition/Disease

    Breast Neoplasms 、Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Dry powder injection Film-coated tablets

Participate Sites
4Sites

Recruiting4Sites

2022-03-01 - 2027-08-31

Phase III

Active
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

  • Condition/Disease

    HER2 Positive Breast Cancer

  • Test Drug

    錠劑

Participate Sites
14Sites

Recruiting14Sites

2025-02-28 - 2032-06-30

Phase III

Active
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  • Condition/Disease

    Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.

  • Test Drug

    Elacestrant

Participate Sites
13Sites

Recruiting13Sites

1 3 4 5 6 7 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB